Review of studies on SARS-CoV-2 infection inhibitors
More details
Hide details
1st Clinical Military Hospital with Outpatient Clinic, Lublin, Poland
Biological Threats Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Warsaw, Poland
Corresponding author
Aleksander Michalski   

1st Clinical Military Hospital with Outpatient Clinic, Racławickei 23, Lublin, Poland
Ann Agric Environ Med. 2021;28(4):541-550
Introduction and objective:
COVID-19 is a human infectious disease manifested by acute respiratory syndrome. On 30 January, 2020, the Word Heath Organization (WHO) declared a COVID-19 pandemic. The purpose of this article is to review publications on the search for substances that show inhibitory activity against SARS-CoV-2 infectivity, paying particular attention to the effect on different stages of the life cycle of the virus.

Review methods:
The review was based on an analysis of the latest available scientific literature and international databases. The data collected relate to the years 2020–2021.

Brief description of the state of knowledge:
Extremely intensive research is underway to find compounds that inhibit infection with the SARS-CoV-2 virus. Promising areas of research among the many current endeavours are antiviral compounds that stimulate the immune system, counter proliferation or affect individual viral replication cycles. These include, among others, interferons, monoclonal antibodies, natural compounds, peptides, aptamers, metal salts, and anti-inflammatory agents, inhibitors of viral enzymem, such as the RNA-dependent RNA polymerase. Preparations that help the body to combat the effects of infection have also assumed much importance.

The ongoing research is focused on the development of new antiviral agents, as well as the use of the existing drugs on the market. The results of clinical trials are promising and give hope for the development of effective therapies against SARS-CoV-2 and emerging variants of this virus.

The authors would like to thank Prof. dr. hab. Stanisław Majcherczyk for his support in suggesting the appropriate scope of coverage of this manuscript.
WHO Coronavirus (COVID-19) Dashboard. Accessed August 1, 2021.
Hartenian E, Nandakumar D, Lari A, et al. The molecular virology of coronaviruses. J Biol Chem. 2020; 295(37): 12910–12934. doi: 10.1074/jbc.REV120.013930.
Rambaut A, Holmes EC, Toole ÁO, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiol. 2021; 5(11): 1403–1407. doi: 10.1038/s41564-020-0770-5.A.
CDC. Science brief: Emerging SARS-CoV-2 variants. Published March 26, 2021. Accessed August 1, 2021.
Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021; 384(23): 2212–2218. doi: 10.1056/nejmoa2105000.
Alibek K, Tskhay A. Ahead of a vaccine: A safe method of protection against COVID-19 exists. Res Ideas Outcomes. 2020; 6. doi: 10.3897/rio.6.e61709.
Pawełczyk A, Zaprutko L. Anti-COVID drugs: Repurposing existing drugs or search for new complex entities, strategies and perspectives. Future Med Chem. 2020; 12(19): 1743–1757. doi: 10.4155/fmc-2020-0204.
McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020; 157(104859): 104859.
Pawlik L, Śpiołek E, Fichna J, et al. Charakterystyka wirusa SARS-CoV-2 i potencjalne farmakologiczne sposoby leczenia. Postępy Biochem. 2020; 66(2): 83–90. doi: 10.18388/pb.2020_321.
Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-?2b against COVID-19: The cuban experience. J Interf Cytokine Res. 2020; 40(9): 438–442. doi: 10.1089/jir.2020.0124.
Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(5): 829–838. doi: 10.1007/s00210-021-02061-x.
Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021; 9(2): 196–206.
Merzon E, Green I, Vinker S, et al. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. FEBS J. 2021; (febs.15784). doi: 10.1111/febs.15784.
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 N Engl J Med. 2021; 384(8): 693–704.
Tardif J-C, Bouabdallaoui N, L’Allier PL, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. bioRxiv. Published online 2021: 2021.01.26.21250494. doi: 10.1101/2021.01.26.21250494.
Manenti L, Maggiore U, Fiaccadori E, et al. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS One. 2021; 16(3): e0248276.
Allocetra-OTS in COVID-19 Phase II. Accessed September 18, 2021.
BioSpace. Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update. Published February 3, 2021. Accessed September 18, 2021.
Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020; 86(106749): 106749.
The U.S. Food and Drug Administration. Information for Olumiant (baricitinib) tablets, for oral use. Access 25 April 2020.
Yang G, Li Z, Mohammed I, et al. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduct Target Ther. 2021; 6(1). doi: 10.1038/s41392-021-00649-6.
Sun M, Liu S, Wei X, et al. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. Angew Chemie – Int Ed. 2021; 60(18): 10266–10272. doi: 10.1002/anie.202100225.
Milewska A, Kaminski K, Ciejka J, Kosowicz K, Zeglen S, et al. HTCC: Broad Range Inhibitor of Coronavirus Entry. Plos One 2016; 11(6): e0156552.
Uckun FM, Saund S, Windlass H, Trieu V. Repurposing anti-malaria phytomedicine Artemisinin as a COVID-19 drug. Front Pharmacol. 2021; 12: 649532.
Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. bioRxiv. 2021: 2021.02.11.21249258. doi: 10.1101/2021.02.11.21249258.
Cohen MS. Monoclonal antibodies to disrupt progression of early covid-19 infection. N Engl J Med. 2021; 384(3): 289–291.
Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020; 324(2): 131–132.
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021; 384(7): 619–629. doi: 10.1056/nejmoa2031304.
Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of Coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021; 191(1): 90–107.
Tirumalaraju D. Celltrion’s Covid-19 drug regdanvimab meets Phase III endpoints. Published June 15, 2021. Accessed August 1, 2021. https://www.clinicaltrialsaren....
RenBio. RenBio completes $24 million series A financing and licenses novel SARS-CoV-2 bispecific antibody from Columbia university. PR Newswire. Published May 20, 2021. Accessed August 1, 2021.
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. medRxiv. 2021: 2021.05.27.21257096.
33. Accessed August 1, 2021.
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19). Accessed August 30, 2021.\.
Ardestani A, Azizi Z. Targeting glucose metabolism for treatment of COVID-19. Signal Transduct Target Ther. 2021; 6(1): 1–2. doi: 10.1038/s41392-021-00532-4.
Larue RC, Xing E, Kenney AD, et al. Rationally designed ACE2-derived peptides inhibit SARS-CoV-2. Bioconjug Chem. 2021; 32(1): 215–223.
Xia S, Zhu Y, Liu M, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020; 17(7): 765–767. doi: 10.1038/s41423-020-0374-2.
Zhao H, Zhou J, Zhang K, et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016; 6(February): 1–13. doi: 10.1038/srep22008.
Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7): 763–772.
Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021; 65(Ivm). doi: 10.1016/j.ebiom.2021.103255.
Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020; 20(1): 1–10. doi: 10.1186/s12879-020-05698-w.
Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020; 396(10259): 1345–1352. doi: 10.1016/S0140-6736(20)32013-4.
Ahmad B, Batool M, Ain QU, Kim MS, Choi S. Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations. Int J Mol Sci. 2021; 22(17): 9124.
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). doi: 10.1126/scitranslmed.aal3653.
Martin U. The Biologics News and Reports Portal. Accessed August 1, 2021.
Good SS, Westover J, Jung KH, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of covid-19. Antimicrob Agents Chemother. 2021; 65(4): 1–12. doi: 10.1128/AAC.02479-20.
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020; 76(4): 370–376. doi: 10.1016/j.mjafi.2020.08.004.
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021; 6(1): 11–18. doi: 10.1038/s41564-020-00835-2.
Fischer W, Eron Jr JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv Prepr. 2021: 1–30.
Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020; 136(18): 2080–2089.
Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E channel blockers from a repurposed drug library. Pharmaceuticals (Basel). 2021; 14(7): 604.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178(104787): 104787.
Bakovic A, Risner K, Bhalla N, et al. Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. bioRxiv. 2020: 2020.10.29.352450.
Aranda-Abreu GE, Aranda-Martínez JD, Araújo R, et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Reports. 2020; 72(6): 1538–1541. doi: 10.1007/s43440-020-00168-1.
Butterworth RF. Potential for the Repurposing of Adamantane Antivirals for COVID-19. Drugs R D. 2021; (0123456789). doi: 10.1007/s40268-021-00351-6.
Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020; 383(21): 2041–2052.
Cirri D, Pratesi A, Marzo T, et al. Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs. Expert Opin Drug Discov. 2021; 16(1): 39–46. doi: 10.1080/17460441.2020.1819236.
Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020; 582(7811): 289–293.
Brendler T, Al-Harrasi A, Bauer R, et al. Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. Phytother Res. 2021; 35(6): 3013–3031.
Signer J, Jonsdottir HR, Albrich WC, et al. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J. 2020; 17(1): 136.
Bernal-Bello D, Morales-Ortega A, Isabel Farfán-Sedano A, de Tena JG, Martín-López JVS. Imatinib in COVID-19: hope and caution. Lancet Respir Med. doi: 10.1016/S2213-2600(21)00266-6.
Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021. doi: 10.1016/S2213-2600(21)00237-X.
Journals System - logo
Scroll to top